18.86
-0.18(-0.95%)
Currency In USD
| Previous Close | 19.04 |
| Open | 19 |
| Day High | 19.3 |
| Day Low | 18.63 |
| 52-Week High | 22.5 |
| 52-Week Low | 8.18 |
| Volume | 867,849 |
| Average Volume | 1.79M |
| Market Cap | 1.45B |
| PE | -6.35 |
| EPS | -2.97 |
| Moving Average 50 Days | 16.87 |
| Moving Average 200 Days | 12.16 |
| Change | -0.18 |
If you invested $1000 in Nurix Therapeutics, Inc. (NRIX) since IPO date, it would be worth $992.11 as of January 16, 2026 at a share price of $18.86. Whereas If you bought $1000 worth of Nurix Therapeutics, Inc. (NRIX) shares 5 years ago, it would be worth $375.92 as of January 16, 2026 at a share price of $18.86.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases
GlobeNewswire Inc.
Jan 12, 2026 12:00 PM GMT
Execute a pivotal program for potential best-in-class BTK degrader, bexobrutideg, including Phase 2 and confirmatory Phase 3 studies to support global registration in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Expand bexobrutideg into
Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 05, 2026 12:00 PM GMT
BRISBANE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncolog
Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition
GlobeNewswire Inc.
Dec 08, 2025 1:00 PM GMT
Objective response rate (ORR) of 75.0% including three very good partial responses (VGPR) in heavily pre-treated Waldenström macroglobulinemia patients With a median follow up of 8.1 months, median duration of response (DOR) and median progression-fr